PTYLTD
    • Free Reports
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Sector

Dimerix (ASX: DXB)

Dimerix (ASX: DXB) Slides Toward $0.19 After Volatile Phase III Trial-Driven Swings

Jun 18, 2026
Proactive Equities Team

Dimerix slipped toward $0.19 after volatile trading driven by its Phase 3 ACTION3 trial. The biotech continues to swing on sentiment as investors react to clinical updates, balancing long-term DMX-200 hopes against no-revenue uncertainty and regulatory timelines.

Clinuvel Pharmaceuticals (ASX: CUV)

Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?

Jun 24, 2026
Proactive Equities Team

CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.

Avecho Biotechnology (ASX: AVE)

Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus

Jun 26, 2026
Proactive Equities Team

Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.

Mesoblast (ASX: MSB)

Mesoblast (ASX: MSB) Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits

Jun 28, 2026
Proactive Equities Team

Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.

Inoviq (ASX: IIQ)

Inoviq (ASX: IIQ)'s Breakout Reverses Hard: IIQ Slides After EXO-OC Study Reset

Jul 2, 2026
Proactive Equities Team

Inoviq shares plunged after sample-quality issues delayed validation of its EXO-OC ovarian cancer test, despite improved algorithm performance. The sharp reversal has shifted investor focus from growth potential to execution risks, timelines, and confidence in the company’s development strategy.

Island Pharmaceuticals (ASX: ILA)

Island Pharmaceuticals (ASX: ILA) Breaks Its Downtrend as Galidesivir News Puts It Back in Play

Jul 8, 2026
Proactive Equities Team

Island Pharmaceuticals has regained market attention after breaking a long-term downtrend, supported by Galidesivir developments and strong trading momentum. Recent updates across biodefence, manufacturing, and intellectual property have improved sentiment, although confirmation above key resistance remains important

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics
Videos

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...4041424344
Page 42 of 44